Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 9/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525063 | 0.86 | GPR119 (0.45) | PTGS1PTGS2LNPEPGPR119NAMPT | |
| SCHEMBL6520019 | 0.85 | PTGS1 (0.47) | ACACBPTGS1PTGS2GPR119NAMPT | |
| SCHEMBL6525322 | 0.85 | P2RX3 (0.39) | LNPEPTIPARPNAMPTHRH3 | |
| SCHEMBL6522050 | 0.84 | LNPEP (0.37) | LNPEPGPR119NAMPTHRH3 | |
| SCHEMBL6525386 | 0.83 | HSD11B1 (0.42) | ACACBGPR119 | |
| SCHEMBL6518444 | 0.83 | CYP11B2 (0.40) | LNPEPGPR119NAMPT | |
| SCHEMBL6522441 | 0.83 | GPR119 (0.41) | ACACBLNPEPGPR119NAMPT | |
| SCHEMBL6522432 | 0.82 | HMOX1 (0.39) | ACACBLNPEPGPR119NAMPTHRH3 | |
| SCHEMBL6525325 | 0.82 | LIPE (0.51) | ACACBLNPEPGPR119NAMPT | |
| SCHEMBL6524790 | 0.82 | NAMPT (0.44) | PTGS1PTGS2NAMPTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | ACACB 3542/4885PTGS1 733/4885PTGS2 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.